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Peripheral Blood Mononuclear Cells Is Differentially Regulated 
By Debra D. Poutsiaka, Burton D. Clark, Edouard Vannier, and Charles A.  Dinarello 
We  studied the relationship between the production of the 
23-Kd interleukin-1 receptor antagonist (IL-lra)  and IL-lp  in 
cultures of human peripheral  blood mononuclear cells (PBMC) 
using a specific radioimmunoassay for  IL-lra that  had  a 
sensitivity of 166 f  11 pg/mL. PBMC cultured  without human 
serum made little IL-lra or IL-lp. In the presence of 1% AB 
serum, there was no increase in IL-1p  (0.25 f  0.13 ng/mL) but 
IL-lra  production increased sevenfold  to  3.4 e  0.5 ng/mL. IgG 
(2.5 to 100 pg/mL IgG) or granulocyte-macrophage  colony- 
stimulating factor (GM-CSF) (1  to 100 ng/mL) had no signifi- 
cant effect on IL-lp  production but increased IL-lra produc- 
tion up to 18-fold (18.2 e 3.9  ng/mL). Using endotoxin as  a 
stimulant, 82% f  2% of IL-lra was secreted in comparison 
with  52%  f  9%  of  IL-1p.  Culture  conditions of  PBMC 
NTERLEUKIN-1 (IL-I) exhibits many different effects  I  in vivo and in vitro.’ Specific inhibitors of  the various 
biologic activities of  IL-1 have been described since the 
early 1980s:  The “IL-1 inhibitor” was initially described as 
a 23- to 25-Kd protein purified from the urine of patients 
with  monocytic  leukemia3J or  from  human  monocytes 
cultured  on  immune  complex-coated surfaces.6 Natural 
IL-1 inhibitor blocked the activity of  IL-1 in several bio- 
assay~.~”~~.~  The IL-1 inhibitor blocked the binding of IL-1 in 
a competitive fashion to receptors on T cells and fibro- 
blast~.~”  This IL-1 inhibitor was  purified from  adherent 
 monocyte^^^'^ and subsequently  was cloned.“ As opposed to 
IL-lp, the cloned protein lacked agonist activity in inducing 
prostaglandin E,  in human dermal fibroblasts.’”  Therefore, 
it  was  renamed  the  interleukin-1  receptor  antagonist 
(IL-lra). An  identical protein was cloned from U937 cells 
and  reported  as  the  IL-1  receptor  antagonist  protein 
The measurement of IL-1 inhibitors has been based on a 
reduction in the activity of  IL-1 in various bioassays. This 
approach  does  not  allow  for  specific and  independent 
measurements of  IL-1 and  IL-lra. Without independent 
assays, the relationship between IL-1 and IL-lra in health 
and disease states cannot be fully explored. Recent studies 
used an enzyme-linked immunosorbant assay (ELISA) for 
IL-lra to study the differential gene expression of  IL-lra 
and IL-lp.” 
We describe here a specific and sensitive radioimmuno- 
assay (RIA) for the measurement  of  IL-lra. Using this 
assay and a specific ELISA for IL-lp, we have studied the 
regulation of the production of  IL-lra and IL-1p proteins 
from peripheral blood mononuclear cells (PBMC) cultured 
in  the  presence  of  endotoxin,  granulocyte-macrophage 
colony-stimulating factor  (GM-CSF),  IgG,  or  IL-1.  In 
addition, we examined the role of  cellular contact in the 
production of IL-lra and IL-1p. 
(IRAP)  .12 
MATERIALS AND METHODS 
Ficoll  type  400 and  endotoxin  (Escherichia coli, 
serotype 055:B5) were obtained from the Sigma Chemical Com- 
pany  (St  Louis,  MO).  Hypaque-M,  90%,  was  obtained  from 
Winthrop Pharmaceuticals (New York, NY).  Sterile pyrogen-free 
water and 0.9% saline were obtained  from Abbott  Laboratories 
Materials. 
influenced the production of  IL-lra but not IL-1s. Rocking 
endotoxin-stimulated PBMC  produced 75% less IL-lra but 
the  same  amount  of  IL-1p when  compared with PBMC 
cultured  in  stationary plastic  tubes. Rocking IgG-or GM-CSF- 
stimulated PBMC  also produced 75% to 80%  less IL-lra. 
GM-CSF or IL-lp  at  concentrations  that elicited submaximal 
production of IL-lra potentiated IgG-induced IL-lra produc- 
tion. The production of IL-lra and IL-1p are under differential 
regulation because serum,  IgG,  and GM-CSF were potent 
stimuli for the production of IL-Ira but not IL-lp, and the 
prevention of cell-cell contact of PBMC reduced IL-lra but 
not IL-1p production. 
0  1991  by The American Society of Hematology. 
(Rockford, IL).  RPMI 1640 culture medium was  obtained  from 
Whittaker  M.A.  Bioproducts  (Walkersville, MD). Ultrafiltration 
filters were  obtained  from Fresenius  AG (Bad  Homburg,  Ger- 
many).  Polypropylene tubes,  12 x  75  mm,  were obtained  from 
Becton  Dickinson  Laboratories  (Lincoln  Park,  IL).  in  the 
di-iodinated form of the Bolton-Hunter reagent was obtained from 
Dupont-New England Nuclear  (Boston, MA). Econo-Pac  lODG 
desalting columns and  Tween-20 were  obtained  from  Bio-Rad 
Laboratories  (Richmond,  CA).  MaxiSorp F96  microtiter  plates 
were  obtained  from  Nunc-Immunoplate  (Roskilde,  Denmark). 
Polyacrylamide  gels (10%) were obtained from Amersham (Arling- 
ton Heights, IL). XAR-5 film was obtained from Kodak (Roches- 
ter,  NY).  An  intensifymg screen,  Cronex Lightening Plus, was 
obtained from Dupont (Wilmington, DE). 
Human IgG, clinical grade suitable for intravenous injection, was 
a gift of Hyland Laboratories (Duarte, CA), and human recombi- 
nant IL-la  was a gift of  Dr Peter Lomedico (Hoffman-LaRoche, 
Nutley, NJ). Human recombinant IL-lp  was a gift of Dr Alan Shaw 
(Glaxo  Institute  for  Molecular  Biology,  Geneva,  Switzerland). 
Human  recombinant  GM-CSF  was  a  gift  of  Dr  Steven  Clark 
(Genetics Institute, Cambridge, MA). Human recombinant IL-lra” 
was a gift of Dr Robert Thompson (Synergen, Boulder, CO). Sheep 
antirabbit IgG was obtained from Ventrex Laboratories (Portland, 
ME). Monoclonal antihuman IL-1p and polyclonal rabbit antihu- 
man IL-1p were the gift of Richard Dondero (Cistron, Pine Brook, 
NJ). ImmunoPure  alkaline phosphatase-conjugated  goat antirab- 
bit IgG and p-nitrophenol phosphate were obtained from Pierce 
(Rockford, IL). 
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Study  population.  The study was  approved  by  the  Human 
Investigation  Review  Committee of  the New  England  Medical 
Center  Hospitals.  Informed  consent  was  obtained  from  each 
subject. Healthy male and female volunteers 20 to 50 years of age 
taking no medications were recruited from laboratory personnel. 
PBMC were isolated from human blood 
as described previ~usly.'~~'~  Some experiments used  human AB 
serum that had been collected under sterile, pyrogen-free condi- 
tions, heated at 56°C for 30 minutes, filtered (0.22-pm pore size), 
and then frozen at -70°C.  PBMCwere incubated in polypropylene 
tubes at 37°C in a humidified atmosphere containing 5%  CO,.  In 
experiments where tubes were rocked, the first hour of incubation 
occurred in the incubator with gentle agitation every 20 minutes, to 
equilibrate the concentration of  CO,.  Tubes were tightly sealed 
with paraffin film and cultured at 37°C on a rocking table set at 20 
cycles/minute. Control experiments showed that tightly sealing the 
culture tubes had no  adverse effect on IL-lra or IL-1$ production 
in stationary tubes (data not shown). Cells were cultured with the 
following:  human  AB  serum,  endotoxin,  human  IgG,  human 
recombinant IL-la, human recombinant IL-l$, and human recom- 
binant GM-CSF. After 20 to 24 hours of incubation, cultures were 
frozen at -70°C  and subjected to three cycles of freeze-thawing 
before assay for IL-lp or IL-lra. In some experiments, cells were 
separated from supernatants by  centrifugation at 1,500g for 10 
minutes at room  temperature.  The resulting cell  pellets were 
resuspended  in  1 mL of  fresh  culture  medium. The cell  and 
supernatant fractions were frozen as described previously. 
Human recombinant IL-lra was radio- 
iodinated with ISI  by the method of Bolton and Hunter.I6  Radiola- 
beled protein was separated from unbound  by chromatography 
on a  desalting column equilibrated with  0.05  mol/L phosphate 
buffer,  pH 7.5,  containing 0.25%  gelatin. The specific activity, 
calculated from the disintegrations per minute (dpm) comprising 
the protein peak, assuming a 70% recovery, ranged from 15 to 77 
pCi/pg. 
Sodium dodecyl sulfa te-polyacrylamide gel  electrophoresis  (SDS- 
PAGE) analysis.  Approximately 10,000 cpm of  '251-IL-lra was 
solubilized in 15 p,L  of loading buffer (62 mmol/L Tris-HC1, pH 
6.8,  10% glycerol,  1% SDS,  1% 2-mercaptoethanol,  0.0005% 
bromophenol blue) and heated at 100°C for 3 minutes. Prestained 
protein molecular weight standards (myosin, M, 30,000; phosphory- 
lase  b,  M,  92,500,  bovine  serum  albumin  [BSA],  M,  69,000; 
carbonic anhydrase, M,  30,000,  trypsin inhibitor, M, 21,500;  and 
lysozyme, M,  14,300) were used on each gel. The gel was dried with 
heat in vacuo and autoradiography was performed by exposure of 
XAR-5 film for 2 days at -70°C  using an intensifying screen. 
A polyclonal anti-IL-lra  antiserum was raised 
in New Zealand white rabbits immunized with IL-lra. Dilutions of 
anti-IL-lra  from 1:100 to 1:6,400 were added to 1251-IL-lra  (10,000 
cpm). After 24 hours at room temperature, immunoprecipitates 
were formed by the addition of sheep antirabbit IgG and polyethyl- 
ene  glycol, at respective final concentrations of 1%  and 3%. After 1 
hour at room temperature, immunoprecipitates were recovered by 
centrifugation  at  1,500g for  15  minutes at room  temperature. 
Dilutions of anti-IL-lra  precipitating approximately 20% of  the 
added "%IL-lra  were used in the RIA. 
Tween-20 and phenylmethylsulfonyl fluoride at final concentra- 
tions of 0.1%  and 1 p,mol/L,  respectively, were added to PBMC 
samples, which were then kept on ice for 1 hour. Undiluted or 
diluted PBMC samples were added to RIA buffer (0.01 mol/L 
phosphate-buffered saline [PBS], pH 7.4,0.25% BSA, and 0.05% 
sodium azide) containing 0.1% Tween-20. Diluted anti-IL-lra  was 
added  to the samples, which  were kept  at room  temperature 
overnight. On the second day, "%IL-lra  (10,000 cpm) was added 
Preparation of  PBMC. 
Radiolabeling of IL-Ira. 
RIA  for IL-Ira. 
to  each  sample.  On  the  third  day,  immunoprecipitates  were 
formed, recovered, and counted as described above. 
The maximum  specific binding was  calculated by  subtracting 
nonspecific binding (cpm precipitated in tubes containing 'SI-IL- 
Ira but no anti-IL-lra  or unlabeled  IL-lra) from total binding 
(cpm immunoprecipitated from tubes containing lSI-IL-lra and 
anti-IL-lra  but no  unlabeled IL-lra). The percent specific binding 
for each sample was calculated by dividing the specific binding of 
the sample by the maximal specific binding and multiplying by  100. 
All samples and standards were run in duplicate. IL-lra concentra- 
tion in each sample was read on  a logit plot of the percent specific 
binding versus the log concentration of a diluted IL-lra standard 
from the linear portion of the curve (usually  between 35% and 85% 
specific binding). 
Human IL-lp was quantified using an 
ELISA."  Standard curves  and IL-lp concentrations in samples 
were determined using  Microplate Manager software (Bio-Rad 
Laboratories) on  a Macintosh SE computer (Apple Computer, Inc, 
Cupertino, CA). The sensitivity of the assay (limit of detection at 
the 95% confidence level) was 40 to 80 pg/mL. 
Statistical  analysis  was  performed  using 
Stat-View software (Abacus Concepts, Inc, Calabasas, CA) on a 
Macintosh SE computer. Two-tailed paired t-tests and analysis of 
variance (ANOVA) using Fisher's least significant difference were 
used. Data are expressed as the mean 2 standard error of  the 
mean (SEM). Differences were considered significant for P < .05. 
Determination of  IL-I$. 
Statistical  analysis. 
RESULTS 
SDS-PAGE ana4si.s of  ZL-lra.  Radiolabeled IL-lra was 
resolved by SDS-PAGE analysis on a 10% polyacrylamide 
gel" to observe its integrity and purity. The autoradiogram 
in Fig 1 shows a single band of  M, 18,000, indicating that 
. -  . .  .- .-  .. - 
= 92500 
= 69000 
n 
-46000  0" 
W 
cn  ~30000 z  -  21 500 
= 14300 
Fig 1.  Autoradiograph of SDS-PAGE analysis of 'WL-lra. Radiola- 
beled IL-lra,  10,000  cpm,  was  resolved by SDS-PAGE on  a  10% 
polyacrylamide gel. 
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IL-lra had not undergone aggregation or breakdown dur- 
ing radioiodination. 
RLA  for IL-lra.  The sensitivity of the assay was 166 & 11 
pglmL, determined from five standard curves. The variation 
in six replicates of a PBMC sample was 5.9%. The assay was 
specific because the presence of IL-la or IL-1p (10 nglmL) 
did not interfere with the measurement of  IL-lra (Fig 2). 
IL-lra (10 ng/mL) added to each tube in the RIA  for IGla 
or IL-1p had no influence on either assay (data not shown). 
Influence of standard culture conditions on IL-lra  produc- 
tion.  Fresh,  uncultured, and lysed  PBMC contained  no 
IL-lra  (data not  shown).  To study the effect  of  normal 
human serum on IL-lra production, PBMC were cultured 
in the presence or absence of  1%  AB serum. Total IL-lra 
and IL-lp were measured (Fig 3). In serum-free medium, 
PBMC produced small amounts of IL-1p or IL-lra. PBMC 
cultured in the presence of serum produced sevenfold more 
IL-lra  compared  with  PBMC  in  serum-free  medium 
(P  < .05).  Maximal production  of  IL-lra (13.6 2 0.8  ngl 
mL) was observed in the presence of  the lowest concentra- 
tion of AB serum tested (0.25%). There was no change in 
the  production  of  IL-lp  when  serum  was  added.  All 
subsequent experiments were performed in the absence of 
serum. 
Differential induction of  IL-lra and IL-1  p production by 
IgG and GM-CSF.  PBMC were cultured in the presence 
of  increasing concentrations of  human IgG, GM-CSF, or 
IL-la. After 24  hours, total IL-lra and IL-1p were mea- 
sured.  As  shown  in  Fig  4A,  human  IgG  was  a  potent 
stimulus for IL-lra production. As little as 1 pg/mL IgG 
induced significant IL-lra production compared with base- 
line (P  < .01). In contrast, the presence of up to 100 pg/mL 
IgG  had  little  effect  on  IL-1p  production  in  the  same 
cultures. 
GM-CSF was also a potent stimulus of IL-lra production 
(Fig 4B).  Significant augmentation  of  IL-lra production 
over baseline was observed in cultures containing as little as 
1  ng/mL (P < .OS). Over the range of concentrations tested, 
there was no effect of GM-CSF on the production of IL-lp. 
The production of IL-1 and other cytokines is influenced 
by  IL-1, interferon, and IL-1ra.19-zz  The effect of  IL-1 on 
IL-lra  production  is  unknown.  Therefore,  PBMC were 
cultured with  IL-la or IL-1p (0.1 to  100 ng/mL) for 24 
I4  --c  noIL-I  E: 
95  - 
M  .-  x  80  - 
tii 
60 - 
40 - 
20 - 
I 
100  1000  10000  100000 
IL-lra (pg/ml) 
Fig 2.  Effect of IL-la  or IL-1g on the standard curve for the IL-lra 
RIA. IL-la  or IL-lg, 10 ng/mL, was added to each tube of diluted IL-lra 
standard. The binding curves for each condition is shown. The data 
are expressed as  the percent binding (left) or  logit binding (right) 
versus the log of the concentration of IL-lra in  pg/mL. 
7  4000 1 
= 
E  3000  . 
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Fig 3.  The effect of 1% AB  serum on the production of IL-lg or 
IL-lra by PBMC.  PBMC were cultured in stationary polypropylene 
tubes in  serum-free medium or in  the presence of 1% AB serum. After 
24 hours, the cultures were harvested and assayed for total IL-lg  or 
IL-Ira. The data from three experiments are expressed as the mean f 
SEM. 
hours and total IL-lra was measured. Although there were 
increases in IL-lra production over baseline levels, they did 
not reach statistical significance (data not shown). 
Cul- 
ture conditions  of  monocytes  influence  their  functional 
state.lssu-zs  Therefore,  PBMC  in  serum-free  medium  or 
stimulated with human IgG or GM-CSF were cultured in 
either stationary or rocking polypropylene tubes. After 24 
The effect of cell-cell contact on IL-lra  Production. 
A 
I 
I  U 
IL-1 p 
m 
Q 
U 
U 
* 
)I 
u  T 
0  .01  .1  1  10  100 
GM-CSF (nglml) 
Fig 4.  The induction of IL-lg  and IL-lra in PBMC by human IgG or 
GM-CSF. PBMC were cultured in  serum-free medium in  the presence 
of increasing  concentrations of human IgG (A)  or GM-CSF (B). After 24 
hours, the cultures were harvested and assayed for total IL-1g and 
IL-lra. Each point represents the mean * SEM of data from three 
individuals. One asterisk indicates statistically significant differences 
compared with baseline for P < .05; three asterisks indicate differ- 
ences for P < .001. 
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Fig 5.  The effect of rocking on IL-lra production by PBMC. PBMC 
were cultured in the presence of serum-free medium, human IgG (A) 
or GM-CSF (B). The tubes either remained stationary or were rocked 
for 24 hours. The cultures were harvested  and assayed for total IL-lra. 
Points represent mean  f  SEM  for  data  from three  experiments. 
Asterisks indicate statistically  significant differences between station- 
ary and rocking cultures at a given concentration of  stimulus (one 
asterisk, P < .05; two asterisks,P < .01). 
hours, total IL-lra was measured. Both IgG (Fig 5A) and 
GM-CSF (Fig 5B) were potent stimuli for IL-lra produc- 
tion in stationary cultures (some of the data are displayed in 
Fig 4). However, in the presence of  IgG, rocking cultures of 
PBMC produced significantly lower levels of  IL-lra. The 
same phenomenon was observed in cultures of  PBMC in 
the presence of  GM-CSF, although the reduction was less. 
We also compared the effect of  these culture conditions 
on the production of  IL-1p and IL-lra in PBMC stimulated 
by  endotoxin. After 24 hours, total IL-16 and IL-lra were 
measured.  Endotoxin  was  a  strong  stimulus  for  IL-lra 
production in stationary cultures (Fig 6A). However, there 
was a substantial reduction in IL-lra production in rocking 
cultures of  endotoxin-stimulated PBMC. In contrast, rock- 
ing had no significant effect on endotoxin-induced  IL-lp 
production (Fig 6B). 
Distribution of  IL-lra  and  IL-1  p between  cellular and 
supematant compartments.  PBMC in stationary polypropy- 
lene tubes were cultured with endotoxin (10 ng/mL). After 
24 hours, cells were separated from supernatants  by centrif- 
ugation. Each fraction was assayed for IL-lp and IL-lra. 
The results  are shown in  Fig  7.  Similar to previous re- 
sult~~~~'  the distribution of  IL-1p  between  cellular  and 
supernatant fractions was variable. In contrast, the distribu- 
tion of  IL-lra between cellular and supernatant compart- 
ments was consistent. Approximately 80% of the IL-lra  was 
20000  - 
E . 
D 
P  - 
A 
I +  stationam 
20000  = 
m  P 
E . 
10000 
U 
r 
4 
0 
0  .1  1  10  100 
Endotoxin (ng/ml) 
B 
---C  stationary  - -  0- -  rocking 
Fig 6.  The  effect of  rocking on IL-lra and IL-lp production by 
PBMC in response to endotoxin. PBMC were cultured in the presence 
of serial dilutions of endotoxin  in stationary or rocking  tubes. After 24 
hours, the cultures were harvested and assayed for IL-lra  (A) or IL-lp 
(B). These data from three donors are expressed as  mean  -c  SEM. 
Asterisks indicate a  statistically  significant  difference between station- 
ary and rocking cultures (P  < .05). 
secreted  into the supernatant. The differences in  IL-lra 
content between the cell-associated and supernatant frac- 
tions was statistically significant (P  < .001). The difference 
between the proportions of  IL-lra and IL-lP in the cell- 
associated fraction was statistically significant as was the 
Q)  loo 1  cell-associated 
IL-1  p  IL-1  ra 
Fig 7.  The distribution of IL-lra  and IL-1p in cellular and superna- 
tant compartments. PBMC were cultured in  the presence of 10 ng/mL 
of  endotoxin. After 24 hours,  culture supernatants were separated 
from cells by centrifugation. Each sample was assayed for IL-1p and 
IL-lra. The bars represent the mean f  SEM  of the percentage of the 
total found in the intracellular or extracellular portions. The data are 
from four experiments. 
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difference between  the proportions  in  the supernatants 
(P < .05). 
Potentiation of  IgG-induced  IL-lra  production by GM-CSF 
or ZL-1 p.  Because low (picogram) levels of  cytokines exist 
in  we  questioned whether  potentiation  of  IgG- 
induced IL-lra production by  GM-CSF or IL-1 existed in 
vitro. PBMC were cultured in stationary tubes for 24 hours 
with IgG (1 pg/mL) in the presence or absence of GM-CSF 
(0.1 ng/mL). These concentrations stimulated submaximal 
production  of  IL-lra when  used  separately  (Fig 4).  In 
addition, PBMC were cultured with IgG (1 pg/mL) with or 
without IL-lp (100 ng/mL). The results are shown in Fig 8. 
Potentiation  of  IgG-induced IL-lra production was  ob- 
served in the presence of  GM-CSF (Fig 8A) or IL-1p (Fig 
8B). 
DISCUSSION 
We have investigated the relationship between IL-lra 
and IL-lp  production by PBMC using an RIA sensitive and 
specific for  IL-lra. This RIA enabled  the independent 
measurement  of  IL-lra in the  same samples containing 
IL-1, a complicated task when using bioassays. The primary 
finding of  these studies was  the existence of  differential 
regulation  of  the  production  of  IL-lra and  IL-1p. This 
conclusion is based on (1) human AB serum, human IgG, 
and  GM-CSF  induced  IL-lra  but  not  IL-lP; (2)  the 
prevention of  cell-cell contact substantially decreased IL- 
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Fig 8.  Potentiation  of IgG-induced IL-Ira production by GM-CSF or 
IL-1p. PBMC were cultured with IgG (I  Fg/mL), OM-CSF (0.1 ng/mL), 
or IgG in combination with GM-CSF (A), or IL-1p (100 ng/mL) with or 
without IgG (B). After 24 hours, IL-Ira was measured. The line within 
the IgG/GM-CSF or  IgG/IL-lp  bar indicates the predicted additive 
effect on cytokine production  of  IgG plus GM-CSF or IgG plus IL-lp. 
The data are expressed as the mean  SEM of three experiments. 
Ira production but had no effect on IGlp production; and 
(3) approximately 80% of  IL-lra produced by  PBMC was 
secreted into the medium whereas only 50% of IL-lp was 
secreted. We also observed the potentiation of IgG-induced 
IL-lra production by  GM-CSF or IL-1p. The existence of 
differential regulation of IL-lra and IL-1p production was 
in agreement with studies on the synthesis of  mRNA for 
each protein.I3 
This and other studies suggest that  IL-lra production 
would occur in tissue rather than in the circulation. Such a 
view is supported by  observations that the production of 
IL-lra or other IL-1 inhibitors similar or possibly identical 
to  IL-lra is  increased  under  conditions associated with 
monocyte  differentiation.  For  example,  IL-lra  or  IL-1 
inhibitor production  increased  in  macrophage-monocyte 
cultures  maintained  for  several weeks with  or without 
GM-CSF3' or in  freshly obtained  PBMC stimulated with 
GM-CSF, as in the present study. In contrast, the preven- 
tion of cell-cell contact (as might occur in the circulation) 
resulted in a marked decrease in IL-lra production. 
The mechanism for the stimulation of IL-lra production 
is unclear. Stimulation by IgG presumably occurs via the Fc 
receptor.  Therefore,  it  is  likely  that  conditions  which 
increase Fc receptor  expression andfor function, such as 
adherenceu324  or exposure to cytokines such as interferon or 
GM-CSF,33  augment IgG-induced IL-lra production. The 
observed potentiation of IgG-induced IL-lra production by 
GM-CSF may be explained by  such a phenomenon.  It is 
unlikely that augmentation of  Fc receptor function is the 
mechanism whereby IL-1p potentiated IgG-induced IL-lra 
production  because  IL-1  does  not  change  Fc  receptor 
function or expression on m0nocytes.3~ 
It is also unclear why the production of IL-lra by  rocking 
PBMC regardless of  the stimulus was  less than  that  by 
stationary PBMC. However, it was apparently not through 
an injurious effect of rocking because IL-1p production by 
the same cells was not affected. It is possible that when 
cell-cell contact or adherence to culture vessels was pre- 
vented, there was reduced synthesis of  a necessary factor 
for  IL-lra  production.  Because  induction  of  IL-1p  by 
endotoxin was unaffected by  rocking, a reduction of  endo- 
toxin receptors is an unlikely explanation. Alternatively, the 
prevention  of  cell-cell contact  or  adherence  to culture 
vessels might  have stimulated the production of  a factor 
that inhibited IL-lra production. 
There is 26% homology between the sequences of IL-lra 
and  IL-1p."  However, there appears to be  a  signal se- 
quence encoded by the IL-lra gene which is lacking in the 
sequence encoded by the IL-lp gene. This implies different 
mechanisms of  secretion for the two proteins."  Disparity 
between the amount of  IL-lra secreted and the amount of 
IL-lp secreted may be explained by  this structural differ- 
ence. 
The relevance of the differential regulation of the produc- 
tion of IGlP  and IL-lra observed in vitro to the pathogene- 
sis of disease is unknown. Certainly, IL-1p is implicated in 
several disease states.' These include septic or endotoxin 
inflammatory  bowel disease,35  and acute myeloge- 
nous le~kemia.'~  It  is  unknown  if  conditions thought  to 
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involve increased IL-1 activity have an accompanying defi- 
ciency in  IL-lra production.  The antagonism of  IL-1 by 
exogenous IL-lra may afford a therapeutic option in these 
diseases.  In  view  of  this,  exogenous  IL-lra  (1)  blunted 
septic shock induced by  Escherichia coli  in rabbits”  and 
baboons  (Dr  Lyle  Moldawer,  personal  communication, 
November 1990); (2) reduced mortality induced by endo- 
toxin  in  rabbits38; (3) blunted  fever  induced  by  IL-1 in 
 rabbit^'^; (4) decreased the inflammation seen in immune 
complex colitis4’; and (5) reduced the spontaneous produc- 
tion of  GM-CSF by and proliferation of  acute myelogenous 
leukemia cells.41 
Intravenous Ig is effective in disorders characterized by 
increased  activity of  the immune  system. These include 
graft-versus-host disease:’  Kawasaki  and im- 
mune thrombocytopenic  One plausible mecha- 
nism  of  action  of  Ig  is  the in  vivo  induction  of  IL-lra 
production.  Given  the  therapeutic potential  of  IL-lra, 
further in vitro and in vivo work is warranted. 
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